By
Trending Posts
Is HEALWELL AI’s Acquisition of BioPharma Canada’s Biggest…
Key Highlights HEALWELL Targets AI-Driven Scale in CRO with $14.4M BioPharma AcquisitionHEALWELL AI Inc. (TSX: AIDX, OTCQX: HWAIF)…
How Merck’s $3B MoonLake Acquisition the AI-Powered Bet…
Key Highlights Merck Moves Decisively: A $3 Billion Signal to the Late-Stage Biotech MarketMerck has reportedly offered over…
Can HekaBio and Alfresa’s AI-Driven Alliance Redefine Japan’s…
Smart Partnerships: HekaBio Leverages Alfresa’s Scale to Localize Global InnovationJapan’s historically delayed access to global therapies may soon…
China focus: Is AstraZeneca’s $5.3B AI-Powered Alliance with…
Key Takeaways: AI as the Catalyst: CSPC’s Dual-Engine Platform Front and CenterAt the core of this partnership lies…
Can Ellipsis Health’s $45M Series A and Launch…
Key Insights: Sage Redefines AI Care Management with Empathy at the CoreEllipsis Health is introducing Sage, an emotionally…
How Tempus AI and Northwestern Use AI to…
Key Takeaways Transforming Alzheimer’s Research with AI and Precision GenomicsIn a multi-year collaboration announced today, Tempus AI (NASDAQ:…
Can Parallel Bio’s $21M Bet on Immune Organoids…
Key Highlights Organoid-AI Platform Aims to Transform Preclinical Drug DiscoveryParallel Bio’s proprietary platform replicates the human immune system…
Can BullFrog AI and Sygnature Discovery’s $30M Alliance…
Key Highlights BullFrog AI Secures Global CRO Partner to Scale AI PlatformBullFrog AI has entered a commercial collaboration…
Can Receptor.AI’s Integration of REAXENSE™ Platform Redefine Full-Stack…
Key Insights: Advanced Chemistry at ScaleReceptor.AI has incorporated the REAXENSE™ platform, developed by Canada-based Reaxense Inc., into its…
Trending Posts
Latest Stories
Can Novo Nordisk’s New Semaglutide and Obesity Pipeline Data at EASD 2025 Redefine ‘Food Noise’ Control, Body Composition, and Cardiovascular Outcomes?
Key Highlights: Scientific Momentum at EASD 2025Novo Nordisk will present 35 abstracts across its diabetes…
Could Pfizer and BioNTech’s LP.8.1-Adapted COMIRNATY® Redefine COVID-19 Protection for High-Risk Adults in 2025-2026?
Key Insights: Robust Phase 3 Findings for High-Risk PopulationsThe topline results from the Phase 3…
Will Merck’s CAPVAXIVE® 21-Valent Vaccine Set a New Benchmark in Pediatric Pneumococcal Protection After Phase 3 Success?
Key Highlights Promising Phase 3 Data from STRIDE-13 TrialMerck announced that CAPVAXIVE demonstrated robust immunogenicity…
Could Sanofi’s One-Time Gene Therapy SAR402663 Transform Treatment for Neovascular Age-Related Macular Degeneration?
Key Highlights A Major Step Forward in Retinal Disease InnovationThe FDA’s Fast Track designation underscores…
Gallery
